Investigation of the role of interleukin-1 receptor antagonist VNTR variant on the Behçet’s disease

dc.contributor.authorDursun, Gul
dc.contributor.authorNursal, Ayşe Feyda
dc.contributor.authorDemir, Helin Deniz
dc.contributor.authorKarakuş, Nevin
dc.contributor.authorDemir, Osman
dc.contributor.authorYiğit, Serbülent
dc.date.accessioned2021-11-01T18:14:54Z
dc.date.available2021-11-01T18:14:54Z
dc.date.issued2018
dc.department[Belirlenecek]
dc.description.abstractObjective: Behçet’s disease (BD), a chronic multisystem inflammatory disorder, is mainly characterized by relapsing periods of a wide range of clinical symptoms. Several cytokine genes may play important roles in the pathogenesis of BD. Therefore, interleukin-1 receptor antagonist (IL-1Ra) gene 86bp variable number tandem repeat (VNTR) variant was investigated in patients with BD in a Turkish population. Methods: One hundred nine patients (60 females, 49 males; the mean age±standard deviation [SD] was 36.56±9.571 years) with BD and one hundred healthy individuals (54 females, 46 males; the mean age±SD was 36.64±2.294 years) were examined in the study. For genotyping, polymerase chain re- action-restriction fragment length polymorphism analysis was employed. Data were analyzed using Statistical Package for Social Sciences (SPSS) 22.0 (IBM Corp.; Armonk, NY, USA) (p<0.05) Results: The genotype distribution and allele frequencies of the IL-1Ra VNTR variant did not differ significantly between the patients and the controls (p>0.05). The frequency of the a1/a1, a1/a2 geno- types and a1, a2 alleles were the most common both in patients and healthy controls (p=0.37, p=0.26, and p=0.53, respectively). Also, no statistically significant difference was found between the IL-1Ra VNTR variant genotypes and clinical characteristics (p>0.05). Conclusion: The results of this study do not support an association between the IL-1Ra VNTR variant and the risk of BD in a Turkish population. However, further studies of this variant with larger sample sizes and different ethnicities are required for confirmation.
dc.identifier.doi10.5152/eurjrheum.2017.16102
dc.identifier.endpage31en_US
dc.identifier.issn2147-9720
dc.identifier.issn2148-4279
dc.identifier.issue1en_US
dc.identifier.pmid29657871
dc.identifier.startpage27en_US
dc.identifier.urihttps://doi.org10.5152/eurjrheum.2017.16102
dc.identifier.urihttps://app.trdizin.gov.tr/makale/TXpBNU5ETTVPUT09
dc.identifier.urihttps://hdl.handle.net/11491/7563
dc.identifier.volume5en_US
dc.identifier.wosWOS:000428850700006
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakTR-Dizin
dc.indekslendigikaynakPubMed
dc.institutionauthor[Belirlenecek]
dc.language.isoen
dc.relation.ispartofEuropean Journal of Rheumatology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectRomatolojien_US
dc.titleInvestigation of the role of interleukin-1 receptor antagonist VNTR variant on the Behçet’s disease
dc.typeArticle

Dosyalar